

## Enrolling Trials at Retina Research Center



Retina Research Center is currently participating in 20 Phase I-III clinical trials, 12 of which are currently enrolling.

### Wet Age-Related Macular Degeneration

**Genentech Archway:** A Phase III study evaluating the efficacy and safety of the Port Delivery System (PDS) with ranibizumab in patients with neovascular AMD

**Genentech Portal:** An open-label extension study evaluating long-term safety and tolerability of the port delivery system (For patients that completed Phase II or Phase III parent study)

**Novartis Merlin:** A Phase III study to assess safety and efficacy of brolocizumab 6mg q4 weeks compared to aflibercept 2mg q4 weeks in patients with neovascular AMD

**Santen 36-002 Avante:** A Phase II Study assessing the efficacy and safety of intravitreal injections of DE-122 in combination with Lucentis compared to Lucentis monotherapy in subjects with neovascular AMD

**Kodiak KSI-CL-101:** A Phase 1b Open-Label study assessing the bioactivity, tolerability and safety of multiple intravitreal injections of KSI-301 in patients with wet AMD, DME and RVO

### Non-proliferative Diabetic Retinopathy

**Boehringer-Ingelheim Protocol 1386.12 ROBIN** - A Phase IIa study evaluating safety and efficacy of oral BI 1467335 in patients with moderate to severe diabetic retinopathy

### Diabetic Macular Edema

**Genentech Yosemite:** A Phase III study to evaluate efficacy and safety of RO6867461 in patients with diabetic macular edema

**Novartis Kestrel:** A Phase III evaluating the efficacy of brolocizumab compared to Eylea in patients with diabetic macular edema.

**Kalvista KVD001-201:** A Phase 2 study to assess safety and efficacy of intravitreal plasma kallikrein inhibitor, KVD001, in patients with center-involved DME who have had prior anti-VEGF treatment

**DRCR AC:** A randomized trial comparing intravitreal Eylea versus intravitreal Avastin and deferred Eylea for treatment of center-involved DME

### Dry AMD - Geographic Atrophy

**Gemini Clarity:** A genetic screening and registry study to evaluate long-term clinical outcomes and disease progression in subjects with non-central GA who are carriers of high-risk genetic complement variants associated with dry AMD

### Macular Telangiectasia

**Mactel NHOR:** A natural history observation and registry study of Macular Telangiectasia Type II

**Neurotech NTMT-03-B Renexus:** A Phase 3 Multicenter, Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2

## CONTACT US

Brian B Berger, MD—[bberger@e-retina.net](mailto:bberger@e-retina.net)

Saradha Chexal, MD—[schexal@e-retina.net](mailto:schexal@e-retina.net)

Ivana Gunderson—[igunderson@e-retina.net](mailto:igunderson@e-retina.net)

Ryan Parmoon—[rparmoon@e-retina.net](mailto:rparmoon@e-retina.net)

Chirag Jhaveri, MD—[cjhaveri@e-retina.net](mailto:cjhaveri@e-retina.net)

Gowtham Jonna, MD—[gjonna@e-retina.net](mailto:gjonna@e-retina.net)

Daniela Wilson—[dwilson@e-retina.net](mailto:dwilson@e-retina.net)

Valerie Gatavaski—[vgatavaski@e-retina.net](mailto:vgatavaski@e-retina.net)

512-279-1251

[www.retinaresearchcenter.com](http://www.retinaresearchcenter.com)